AddLife reported a 4 percent increase in net sales for Q3 2025, reaching SEK 2,429 million, with organic growth at 6 percent. EBITA, excluding one-off costs, rose by 17 percent to SEK 270 million, resulting in an EBITA margin of 11.1 percent. Profit after tax significantly increased by 228 percent to SEK 82 million, and earnings per share reached SEK 0.66. For January to September 2025, net sales increased by 3 percent to SEK 7,709 million, with organic growth of 4 percent. EBITA, excluding one-off costs, increased by 12 percent to SEK 920 million, yielding an EBITA margin of 11.9 percent. Profit after tax increased by 89 percent to SEK 302 million, and earnings per share amounted to SEK 2.47. The equity ratio stood at 42 percent, and return on working capital was 55 percent.
Good organic growth and strong earnings development “AddLife’s companies performed strongly during the quarter. Organic growth was solid, margin improvement continued, earnings increased significantly, and the debt ratio was reduced, in line with our priorities and ambitions.” Fredrik Dalborg, President and CEO
Net sales increased by 4 percent to SEK 2,429m (2,344). The organic growth, excluding exchange rate changes, was 6 percent and the acquired growth was 1 percent.
EBITA excl. one-off costs increased by 17 percent to SEK 270m (230), corresponding to an EBITA margin of 11.1 percent (9.8).
Profit after tax increased by 228 percent to SEK 82m (25).
Earnings per share amounted to SEK 0.66 (0.19).
Cash flow from operating activities amounted to SEK 145m (137).
JANUARY – SEPTEMBER, 2025
Net sales increased by 3 percent to SEK 7,709m (7,468). The organic growth, excluding exchange rate changes, was 4 percent and the acquired growth was 1 percent.
EBITA excl. one-off costs increased by 12 percent to SEK 920m (819), corresponding to an EBITA margin of 11.9 percent (11.0).
Profit after tax increased by 89 percent to SEK 302m (160).
Earnings per share amounted to SEK 2.47 (1.30). Earnings per share for the last 12 months amounted to SEK 3.23 (0.98).
Cash flow from operating activities amounted to SEK 504m (429).
The equity ratio was 42 percent (41).
Return on working capital (P/WC) amounted to 55 percent (51).
In April, the acquisition of Edge Medical Ltd., United Kingdom, was completed. The acquisition is expected to contribute annual net sales of approximately SEK 90m.
Stockholm, October 23, 2025 AddLife AB (publ)
AI Summary Disclaimer BETA
The content you are viewing has been generated or assisted by artificial intelligence (AI). While efforts are made to ensure accuracy and clarity, AI-generated text may contain inaccuracies, outdated information, or subjective interpretations. This content is intended for general informational purposes only and should not be considered professional advice or factual confirmation.
We encourage you to independently verify any information provided, especially if it will be relied upon for making decisions or taking action. Any reliance you place on this material is strictly at your own risk. The AI system that produced this content cannot assess the specifics of individual circumstances, and results may vary based on context and individual needs.
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.